Revenue segments as reported by the company.

Women’s Health

Biosimilars

Established Brands

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Acquired in-process research and development and milestones

Interest expense

Exchange losses (gains)

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Organon & Co

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organon & Co reports strong Q4 earnings, eyes growth opportunities

Organon & Co's Q4 2022 earnings call highlighted robust financial performance, strategic initiatives in key segments, and a positive outlook for future growth. Despite challenges in China and market dynamics, the company remains focused on leveraging its strengths, addressing challenges, and capitalizing on growth opportunities to drive shareholder value and portfolio expansion.

Organon & Co reports solid Q1 performance and eyes growth opportunities

Organon & Co's Q1 2023 performance reflects revenue growth, margin improvement, and strategic investments in key franchises and medical devices.
The company's strengths lie in financial discipline, strong segment performance, and growth opportunities in fertility markets and biosimilars.
Challenges include inflationary pressures, competitive pricing scenarios, and the need to address loss of exclusivity and pricing dynamics.
Opportunities exist in expanding market presence in Asia Pacific, launching new products, and focusing on sustainable growth through financial prudence.

Organon & Co reports solid Q2 earnings, eyes growth opportunities

Organon & Co's Q2 2023 performance showed revenue growth, margin improvement, and strategic focus on key business segments.
Strengths in product differentiation, market positioning, and growth drivers position the company for continued success.
Challenges in revenue drivers, market expansion, and financial strategy require strategic adjustments for sustained growth.
Opportunities in Women's Health, biosimilar portfolio, and market penetration strategies offer avenues for future growth and market leadership.

Organon reports mixed Q3 results, eyes biosimilar growth opportunities

Organon's Q3 performance showed mixed results with challenges in women's health and biosimilar uptake, but stable growth in established brands.
The company is focusing on cost efficiency, portfolio optimization, and market expansion in biosimilars for future revenue growth.
Despite near-term challenges, Organon remains optimistic about its financial outlook, especially with opportunities in biosimilars and market expansion strategies.
Strategic shifts towards retail sector in China and product optimization are key focus areas for sustained growth and profitability.

Organon & Co reports solid Q4 earnings, eyes strategic growth

Organon's Q4 2023 earnings call showcased strong financials, strategic partnerships, and a focus on cost management. The company aims for low single-digit revenue growth in 2024 and $1 billion in free cash flow.

Organon & Co reports strong Q1 performance, eyes biosimilar growth

Organon & Co's Q1 2024 showcased robust revenue growth and strategic financial planning
Challenges include flat global fertility business and cautious outlook due to foreign exchange dynamics
Opportunities lie in expanding biosimilar market, margin expansion, and transformative deals

Organon & Co reports solid Q2 earnings, eyes franchise growth

Organon & Co's Q2 2024 performance reflects a mix of solid revenue growth and margin stability.
While facing challenges in certain regions and franchise segments, the company maintains a focus on growth.
Strategic opportunities lie in expanding key franchises, regulatory milestones, and operational efficiency.
Overall, Organon & Co remains optimistic about sustained revenue growth and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will release third quarter 2023 financial results on November 2, 2023, prior to the webcast and conference call scheduled for 8:30 a.m. EST.

Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023

American Airlines

Comerica

Invesco

PG&E

AT&T

Valero Energy

Verizon

Why bother with S&P 500 stocks when you can get a 5% yield from bonds? Simple. Stocks yield more than just dividends.

8 Stocks Sporting 20% 'Aggregate' Yields Are Worth Your While

Activision Blizzard

Hubbell

Lululemon Athletica

Onto Innovation

NEW YORK , Oct. 13, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the opening of trading on Wednesday, October 18: Lululemon Athletica Inc. (NASD:LULU) will replace Activision Blizzard Inc. (NASD:ATVI) in the S&P 500. S&P 500 and S&P 100 constituent Microsoft Corp. (NASD: MSFT) acquired Activision Blizzard in a transaction completed today, October 13.

Lululemon Athletica & Hubbell Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

The stock of junk-rated Organon & Co. has lost more than 40% since my first article, largely due to interest rates continuing to rise. I take a close look at the company's debt and how I think the situation will evolve until 2028 - when OGN will have to refinance most of its debt. Besides a brief update on Organon's Q2 performance, I explain why the company's debt situation remains manageable even under a "higher for longer" scenario.

Organon: The Federal Reserve Black Swan (Rating Upgrade)

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Recognized on Fortune's 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice.

Organon Recognized on Fortune's 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice

Organon & Co. stock is down 30% year-to-date and 40% below its 52-week highs. OGN offers a dividend yield of 5.8%, making it an attractive option for income-oriented investors. The company has a stable revenue base and potential for future dividend hikes as debt decreases.

6% Yield And Significantly Undervalued: A Closer Look At Organon

GlaxoSmithKline

Viatris

Viatris, known for its branded drugs, has several up-and-coming biosimilars. GSK is seeing sales growth even as its COVID-19-related sales decline.

3 Pharmaceutical Stocks That Are Too Cheap to Ignore

Alaska Air Group

DXC Technology

Lincoln National

Mohawk Industries

Newell Brands

Sealed Air

Zions Bancorp

Getting booted out of the S&P 500 is a mark of shame most companies try to avoid. But it's a harsh possibility several face.

8 Stocks Face Highest Risk Of Getting Booted Out Of The S&P 500

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Bolsters Research & Development Expertise with Two Leadership Appointments.

Organon Bolsters Research & Development Expertise with Two Leadership Appointments

Organon & Co (NYSE:OGN ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Sandra Milligan - Head of R&D Conference Call Participants David Amsellem - Piper Sandler Umer Raffat - Evercore Jason Gerberry - Bank of America Navann Ty - BNP Paribas Exxon Chris Shibutani - Goldman Sachs Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon Second Quarter 2023 Earnings Conference Call.

Organon & Co (OGN) Q2 2023 Earnings Call Transcript

Organon & Co reported better-than-expected second-quarter results on Tuesday, helped by strong demand for its women's heath products and biosimilar drugs, sending the healthcare firm's shares up about 8%.

Organon results beat estimates on demand for women heath products, biosimilars

While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Organon (OGN) Reports Q2 Earnings: What Key Metrics Have to Say

Organon (OGN) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $1.25 per share a year ago.

Organon (OGN) Q2 Earnings and Revenues Beat Estimates

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Results for the Second Quarter Ended June 30, 2023.

Organon Reports Results for the Second Quarter Ended June 30, 2023

Dominion Energy

Organon, Dominion Energy, and AT&T are all high-yielding stocks that pay more than 5%. Organon and Dominion have stable businesses that should provide consistent results.

Need an Extra $4,000 in Dividends Each Year? Invest $68,000 in These 3 Stocks.

Organon, a global healthcare company, is a buy for value and income investors due to its strong growth in biosimilars business and 5.5% dividend yield. Despite a 20% YoY decline in adjusted EBITDA, the company has seen constant currency product sales growth for six consecutive quarters and is paying down debt. Risks to Organon include higher interest rates and increased competition, but these are considered to be already factored into the current share price.

Organon: Big Dividend And Upside Potential

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023.

Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023

Organon & Co. OGN, -1.15% and partner Samsung Bioepis Co. Ltd. said Wednesday they have launched their Humira biosimilar Hadlima in the U.S. The move comes after Humira, AbbVie' Inc.'s ABBV, +0.21% rheumatoid arthritis drug that is one of the best selling biopharma products of all time, was opened to biosimilar competition on July 1 after losing its U.S. exclusivity earlier this year.

Organon and Samsung Bioepis launch Humira biosimilar Hadlima in the U.S.

Invitation Homes

Vici Properties

Survivorship bias is one of the biggest issues when selecting buy and hold stocks to own for the next 50 years.  What is survivorship bias?

3 S&P 500 Stocks to Own for the Next 50 Years

Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis drug Humira, while two other drugmakers entered the market with much more modest discounts to the branded medicine's list price.

Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount

AbbVie

Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis drug Humira, while another drugmaker entered the market with a much more modest discount to the branded medicine's list price.

Organon, Samsung Bioepis launch copycat for athritis drug Humira at 85% discount

JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator.

Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator

Enbridge

Organon & Co., Enbridge, and Dominion Energy provide investors with above-average yields. Each stock's payout ratio seems manageable, with room for dividend payments to grow.

Want $5,000 in Annual Dividend Income? Invest in These 3 Stocks

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals.

News for Organon & Co Stock (OGN)